<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159911">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02092194</url>
  </required_header>
  <id_info>
    <org_study_id>KHSG-201301</org_study_id>
    <nct_id>NCT02092194</nct_id>
  </id_info>
  <brief_title>High Versus Standard Volume Hemodiafiltration in Asia</brief_title>
  <official_title>Effectiveness of High-volume Online Hemodiafiltration Compared to Standard Volume Online Hemodiafiltration. A Prospective, Multicenter, Randomized, Open-labelled Interventional Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korean Hemodialysis Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korean Hemodialysis Study Group</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Online hemodiafiltration (HDF) may improve clinical outcome in end-stage renal disease. The
      supported mechanism is the improved clearance of uremic toxins by convective transporter.
      However, It has not been elucidated which convection volume is optimal, especially in Asia.
      A total of 60 participants receiving conventional hemodialysis will be randomly assigned to
      receive either high dose convective volume (33-43 L/treatment) post-dilution online HDF or
      standard dose (16.8-21.5 L/treatment) for 24 weeks. The primary outcome is the change of
      serum β2 microglobulin levels between baseline and after 24 weeks. The secondary outcomes
      will include changes in the nutritional markers, inflammatory markers, and blood pressure
      from baseline to after treatment.

      This would be the first multicenter prospective, randomized controlled trial to determine
      whether large convective volume improves the treatment efficacy in Korean patients
      undergoing post-dilution online HDF.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>changes in the serum concentration of β2 microglobulin</measure>
    <time_frame>between baseline and 24 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dialysis Adequacy</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Kt/V by the single pool variable volume formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>C-reactive protein (CRP), interleukin-6, tumor necrosis factor-α.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>normalized protein nitrogen appearance rate, serum albumin, serum protein, subjective global assessment (SGA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intradialytic hypotension</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of episode of symptomatic hypotension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>baseline and 24 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>SF-36-K (Korean version)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Standard Dose online HDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Proposed target convection volume; 16.8-21.5 L/treatment (70-90 mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose online HDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proposed target convection volume; 33-43 L/treatment (140-180 mL/min).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High Dose Online HDF</intervention_name>
    <description>Convection volume; 33-43 L/treatment (140-180 mL/min)</description>
    <arm_group_label>High Dose online HDF</arm_group_label>
    <other_name>High Volume online hemodiafiltration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard Dose Online HDF</intervention_name>
    <description>convection volume; 16.8-21.5 L/treatment (70-90 mL/min)</description>
    <arm_group_label>Standard Dose online HDF</arm_group_label>
    <other_name>Standard Volume online hemodiafiltration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients on thrice-weekly standard hemodialysis for &gt; 3 months

          -  Patients with a vascular access capable of delivering consistently a high blood flow
             rates ( ≥ 300 mL/min)

          -  Patients willing to provide written informed consent.

        Exclusion Criteria:

          -  Patients with active infectious or uncontrolled inflammatory disorders

          -  Patients with any uncontrolled malignant disease

          -  Patients with recent major cardiovascular disease during the last 6 months

          -  Patients who are likely to receive kidney transplant within the following 1 year

          -  Patients whose life expectancy &lt; 12 months

          -  Patients considered by investigator to have difficulty in participation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won-Yong Cho, MD</last_name>
    <role>Study Director</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung Gyun Kim, MD</last_name>
    <phone>+82-10-3586-8561</phone>
    <email>imnksk@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Soo Jin Kim, MD</last_name>
    <phone>+82-10-8722-8078</phone>
    <email>dongangagy@lycos.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sung Gyun Kim, MD</last_name>
      <phone>+82-31-380-3976</phone>
      <email>imnksk@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Soo Jin Kim, MD</last_name>
      <phone>+82-10-8722-8078</phone>
      <email>dongangagy@lycos.co.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Sung Gyun Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Soo Jin Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Su-Hyun Kim, MD</last_name>
      <email>sh76so@cau.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Su-Hyun Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyeong Cheon Park, MD</last_name>
      <email>amp97@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Hyeong Cheon Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Won-Yong Cho, MD</last_name>
      <email>wonyong@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Won-Yong Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shamyook Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sun Ryoung Choi, MD</last_name>
      <email>ryounge@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Sun-Ryoung Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kwon Wook Joo, MD</last_name>
      <email>junephro@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Kwon Wook Joo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>March 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korean Hemodialysis Study Group</investigator_affiliation>
    <investigator_full_name>Sung Gyun Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>beta 2-Microglobulin</keyword>
  <keyword>Hemodiafiltration</keyword>
  <keyword>convective volume</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
